Plain-English translation of NCT07435701 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new treatment called for women with advanced ovarian cancer who have developed a large buildup of fluid in their abdomen (called ascites). The medication uses specially activated immune cells from healthy donors that are injected directly into the abdomen to help the body recognize and attack cancer cells. This treatment aims to shrink the fluid buildup and improve quality of life.
Advanced ovarian cancer often causes painful fluid to accumulate in the abdomen, which significantly worsens symptoms and shortens survival. Standard treatments don't always work well for this problem, so researchers are testing whether this new immune cell therapy can directly target cancer cells in the abdomen and reduce this dangerous fluid buildup.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will receive four injections of the medication directly into your abdomen, given once a week over four weeks (on days 1, 8, 15, and 22). Researchers will closely monitor you for side effects and measure how the treatment affects your fluid buildup, cancer, and overall health through blood tests, imaging, and symptom assessments. The study will track your progress for at least one year to see how long the benefits last and whether this treatment helps you live longer.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China